[{"id":"88ad40d2-3f3c-42ee-9ab2-c0a562d28c8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828069","created_at":"2023-04-25T14:03:34.544Z","updated_at":"2025-02-25T14:09:38.080Z","phase":"Phase 2","brief_title":"A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis","source_id_and_acronym":"NCT05828069","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ERBB3","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ERBB3 mutation","tags":["BRAF • ALK • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ERBB3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"a7437321-346d-40a3-ad9b-7749466b632b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02673398","created_at":"2021-01-17T17:30:55.191Z","updated_at":"2024-07-02T16:35:45.421Z","phase":"Phase 2","brief_title":"Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer","source_id_and_acronym":"NCT02673398","lead_sponsor":"City of Hope Medical Center","biomarkers":" ERBB3","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 L755P • ERBB3 mutation • HER-2 S310Y • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • ERBB3 V659E • HER-2 G778_S779insCPG • HER-2 L755_T759del • HER-2 A775 • HER-2 D769H • HER-2 R678Q • HER-2 R896C • HER-2 YVMA • ERBB3 L755S","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 L755P • ERBB3 mutation • HER-2 S310Y • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • ERBB3 V659E • HER-2 G778_S779insCPG • HER-2 L755_T759del • HER-2 A775 • HER-2 D769H • HER-2 R678Q • HER-2 R896C • HER-2 YVMA • ERBB3 L755S"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/02/2016","start_date":" 12/02/2016","primary_txt":" Primary completion: 03/12/2020","primary_completion_date":" 03/12/2020","study_txt":" Completion: 09/22/2022","study_completion_date":" 09/22/2022","last_update_posted":"2023-06-16"},{"id":"c5f60531-65fd-4bcb-88b3-780e1307cb1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05512182","created_at":"2022-08-23T14:55:32.104Z","updated_at":"2024-07-02T16:35:45.560Z","phase":"Phase 2","brief_title":"Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression","source_id_and_acronym":"NCT05512182","lead_sponsor":"Yonsei University","biomarkers":" EGFR • HER-2 • ERBB3 • ERBB4","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation","tags":["EGFR • HER-2 • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Nerlynx (neratinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2023-06-15"},{"id":"9cf35a0d-6589-4c60-9d42-5fee66ab236e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769764","created_at":"2023-03-15T14:02:25.719Z","updated_at":"2024-07-02T16:35:50.990Z","phase":"","brief_title":"A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05769764","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KRAS • ALK • ERBB3","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • ERBB3 expression • KRAS G12 • EGFR exon 20 mutation • ERBB3 mutation","tags":["KRAS • ALK • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • ERBB3 expression • KRAS G12 • EGFR exon 20 mutation • ERBB3 mutation"],"overall_status":"Completed","enrollment":" Enrollment 225","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 04/06/2023","primary_completion_date":" 04/06/2023","study_txt":" Completion: 04/06/2023","study_completion_date":" 04/06/2023","last_update_posted":"2023-04-10"},{"id":"46df8032-2537-4032-a30a-3425efd6b937","acronym":"LUX-Bladder 1","url":"https://clinicaltrials.gov/study/NCT02780687","created_at":"2021-01-18T13:38:22.676Z","updated_at":"2024-07-02T16:36:38.566Z","phase":"Phase 2","brief_title":"Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy","source_id_and_acronym":"NCT02780687 - LUX-Bladder 1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR • HER-2 • ERBB3","pipe":" | ","alterations":" HER-2 amplification • HER-2 mutation • EGFR amplification • ERBB3 mutation","tags":["EGFR • HER-2 • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 mutation • EGFR amplification • ERBB3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 06/09/2016","start_date":" 06/09/2016","primary_txt":" Primary completion: 09/24/2018","primary_completion_date":" 09/24/2018","study_txt":" Completion: 09/02/2019","study_completion_date":" 09/02/2019","last_update_posted":"2020-11-18"},{"id":"5004fdcd-2265-4417-a030-cd9831db3315","acronym":"","url":"https://clinicaltrials.gov/study/NCT03810872","created_at":"2021-01-18T18:49:47.326Z","updated_at":"2024-07-02T16:37:03.639Z","phase":"Phase 2","brief_title":"An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation","source_id_and_acronym":"NCT03810872","lead_sponsor":"AZ-VUB","biomarkers":" EGFR • HER-2 • ERBB3","pipe":" | ","alterations":" EGFR mutation • ERBB3 mutation","tags":["EGFR • HER-2 • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ERBB3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 06/21/2017","start_date":" 06/21/2017","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2019-01-22"}]